[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054233":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":22,"centralContacts":32,"locations":22,"responsibleParty":38,"collaborators":22,"id":40,"slug":22,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":22,"eligibilityCriteria":44,"healthyVolunteers":41,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":22,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":22,"overallStatus":61,"whyStopped":22,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":22},{"fullName":5,"class":6},"Hematology department of the 920th hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Triple Therapy to Reduce DSA in Haploidentical HSCT: A Prospective Multicenter Study","EXPERIMENTAL","Participants receive dexamethasone (25 mg\u002Fm² × 4 days) and intravenous immunoglobulin (1 g\u002Fkg) prior to haploidentical hematopoietic stem cell transplantation, plus an additional dose of donor mononuclear cells on transplant day. The additional dose is stratified by baseline DSA MFI level: ≤5000: +2±2×10⁸\u002Fkg; 5000-10000: +4±2×10⁸\u002Fkg; \\>10000: +6±2×10⁸\u002Fkg.",[13,14,15],"Biological: Intravenous Immunoglobulin","Drug: Dexamethasone","Biological: Mononuclear Cells",[17,23,28],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"BIOLOGICAL","Intravenous Immunoglobulin","1 g\u002Fkg intravenously on day -1 prior to transplant.",[9],null,{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":22},"DRUG","Dexamethasone","25 mg\u002Fm² intravenously for 4 days prior to transplant (days -4 to -1).",[9],{"type":18,"name":29,"description":30,"armGroupLabels":31,"otherNames":22},"Mononuclear Cells","Additional donor MNCs infused on day 0. Dose stratified by baseline DSA MFI level: ≤5000: +2±2×10⁸\u002Fkg; 5000-10000: +4±2×10⁸\u002Fkg; \\>10000: +6±2×10⁸\u002Fkg.",[9],[33],{"name":34,"role":35,"phone":36,"phoneExt":22,"email":37},"Sanbin Wang","CONTACT","+8613187424131","sanbin1011@163.com",{"type":39,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100054233",false,"NCT07698080","Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploid Hematopoietic Stem Cell Transplantation: a Prospective, Multicenter Study","Inclusion Criteria:\n\n1. Diagnosis of benign or malignant hematological diseases (including leukemia, lymphoma, thalassemia, aplastic anemia, myelodysplastic syndromes, etc.) confirmed by NCCN guidelines, and determined by the investigator to require allogeneic hematopoietic stem cell transplantation.\n2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3.\n3. Donor-specific antibody (DSA) mean fluorescence intensity (MFI) \\> 500.\n4. Age between 18 and 65 years (age limits are also captured separately in the eligibility module).\n5. Body weight between 40 kg and 100 kg.\n6. No other suitable donor available (i.e., no DSA-negative related donor or unrelated donor).\n\nExclusion Criteria:\n\n1. Patients unsuitable for transplantation or without willingness to undergo transplantation, or diagnosed with non-hematological diseases.\n2. Estimated life expectancy \\\u003C 1 month.\n3. Known allergy to any drug or intervention used in the study regimen.\n4. Pregnancy, lactation, active severe infection, or severe major organ dysfunction.\n5. Severe psychiatric or neurological disorders that may affect the ability to provide informed consent and\u002For to report adverse events or comply with observation.\n6. Refusal or inability to sign the informed consent form.","ALL","18 Years","65 Years",{"count":49,"type":50},60,"ESTIMATED","INTERVENTIONAL",[53],"PHASE2","This study tests whether a combination of three treatments - dexamethasone (a steroid), intravenous immunoglobulin (IVIG, a protein that helps the immune system), and an extra dose of donor mononuclear cells - can safely lower harmful antibodies called donor-specific antibodies (DSA) in patients who need a stem cell transplant from a half-matched (haploidentical) family donor.\n\nIn these transplants, DSA are antibodies made by the patient's own body that attack the donor's stem cells. If DSA levels are high, the transplant is more likely to fail - the donor cells may not \"take\" (engraft). Currently, there is no single, simple, and reliable way to reduce DSA, and many existing methods have drawbacks.\n\nBased on our earlier experience in 11 patients, this three-part approach seemed to work well. All patients successfully engrafted, and DSA levels dropped quickly. Now we want to confirm these results in a larger, prospective, multicenter study.\n\nWe plan to enroll 60 patients aged 18-65 with blood cancers or other blood disorders who need a haploidentical transplant, have DSA levels above 500 MFI (a measure of antibody strength), and have no other suitable donor available. Participants will receive:\n\n* Dexamethasone (25 mg\u002Fm²) for 4 days before transplant,\n* IVIG (1 g\u002Fkg) one day before transplant,\n* Extra mononuclear cells on transplant day - the extra amount depends on how high their DSA level is (low, medium, or high).\n\nThe main goal is to see how many patients have primary graft failure (when the donor cells never engraft). We will also measure how long it takes for blood counts to recover, rates of graft-versus-host disease, survival, and side effects. All participants will be followed for 1 year.\n\nThis study will help us find out whether this combination is a safe, simple, and effective way to improve transplant success for patients with DSA who have no other donor options.",[56,57,58,59,60],"Leukemia","Lymphoma","Thalassemia","Aplastic Anemia","Myelodysplastic Syndromes","NOT_YET_RECRUITING","2026-07-07",{"date":64,"type":65},"2026-07-13","ACTUAL",{"date":67,"type":50},"2026-07-03",{"date":69,"type":50},"2028-07-03",{"name":5,"class":6}]